ArticleNeuroscience letters2011
Acamprosate reduces ethanol drinking behaviors and alters the metabolite profile in mice lacking ENT1.
Article in Neuroscience letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- FDA approved drug containing acetamide group- a mini review.Frontiers in chemistry · 2026Review
- Next-generation biomarkers for alcohol consumption and alcohol use disorder diagnosis, prognosis, and treatment: A critical review.Alcohol, clinical & experimental research · 2025Review
- Chronic caffeine exposure in adolescence promotes diurnal, biphasic mood-cycling and enhanced motivation for reward in adult mice.Behavioural brain research · 2019Article
- Effects of Ethanol Exposure on the Neurochemical Profile of a Transgenic Mouse Model with Enhanced Glutamate Release Using In VivoNeurochemical research · 2019Article
- Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model.Proteomics · 2018Article
- Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects.Scientific reports · 2017Article
- Commentary: Targeting NMDA Receptor and Serotonin Transporter for the Treatment of Comorbid Alcohol Dependence and Depression.Alcoholism, clinical and experimental research · 2017Article
- Glutamate plasticity woven through the progression to alcohol use disorder: a multi-circuit perspective.F1000Research · 2017Review
- Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice.Alcoholism, clinical and experimental research · 2016Article
- Methanolic Extract ofFrontiers in pharmacology · 2016Article
- Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate.Translational psychiatry · 2014Article
- Article
- Striatal adenosine signaling regulates EAAT2 and astrocytic AQP4 expression and alcohol drinking in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders.Bioanalysis · 2012Review
- Adenosine and glutamate signaling in neuron-glial interactions: implications in alcoholism and sleep disorders.Alcoholism, clinical and experimental research · 2012Review
- Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1.Neuropharmacology · 2012Article
- Type 1 equilibrative nucleoside transporter regulates ethanol drinking through accumbal N-methyl-D-aspartate receptor signaling.Biological psychiatry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Acamprosate is clinically used to treat alcoholism. However, the precise molecular functionality of acamprosate in the central nervous system remains unclear, although it is known to antagonize glutamate action in the brain. Since elevated glutamate signaling, especially in the nucleus accumbens (NAc), is implicated in several aspects of alcoholism, we utilized mice lacking type 1 equilibrative nucleoside transporter (ENT1), which exhibit increased glutamate levels in the NAc as well as increased ethanol drinking behaviors. We found that acamprosate significantly reduced ethanol drinking of mice lacking ENT1 (ENT1(-/-)) while having no such effect in wild-type littermates. We then analyzed the basal and acamprosate-treated accumbal metabolite profiles of ENT1(-/-) and wild-type mice using in vivo 16.4T proton magnetic resonance spectroscopy (MRS). Our data show that basal glutamate+glutamine (Glx), glutamate, glutamine and N-acetylaspartatic acid (NAA) levels are increased in the nucleus accumbens (NAc) of ENT1(-/-) compared to wild-type mice. We then found that acamprosate treatment significantly reduced Glx and glutamine levels while increasing taurine levels in the NAc of only ENT1(-/-) compared to their saline-treated group while normalizing other metabolite compared to wild-type mice. This study will be useful in the understanding of the molecular basis of acamprosate in the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.